Department of Pharmacology, National University of Singapore, 117597, Singapore.
Expert Opin Ther Targets. 2010 Aug;14(8):855-68. doi: 10.1517/14728222.2010.499361.
The Hippo signaling pathway plays pivotal roles in controlling both cell growth and organ size, emerging as a new paradigm in tumor suppression. Yes-associated protein (YAP) functions as a potent transcription co-activator and is a major downstream target tightly regulated by the Hippo pathway. Inactivation of the Hippo signaling induces YAP-mediated activation of various target genes that functionally causes cellular proliferation and outgrowth of organ size. Recently, YAP has been implicated as a bona fide oncogene in solid tumors, but little is known about its exact molecular mechanism in carcinogenesis.
We discuss the latest important findings in the Hippo signaling pathway and the possible means of developing potential cancer therapeutics by targeting multiple sites along the Hippo pathway.
An overview of the emerging roles of YAP and Hippo signaling in oncogenesis and the possible ways of developing cancer therapies against the pathway components, downstream targets or interconnected pathways.
YAP is a key oncogenic driver in liver carcinogenesis and deregulation of the Hippo pathway causes tumor formation and malignancy. Targeting YAP and cognate downstream signaling targets may have clinical utility in cancer therapies.
Hippo 信号通路在控制细胞生长和器官大小方面发挥着关键作用，它是肿瘤抑制的新范例。Yes 相关蛋白（YAP）作为一种有效的转录共激活因子，是 Hippo 通路紧密调控的主要下游靶标。Hippo 信号通路的失活会诱导 YAP 介导的各种靶基因的激活，这些基因在功能上导致细胞增殖和器官大小的过度生长。最近，YAP 被认为是实体肿瘤中的真正癌基因，但关于其在致癌作用中的确切分子机制知之甚少。
我们讨论了 Hippo 信号通路的最新重要发现，以及通过靶向 Hippo 通路多个位点开发潜在癌症治疗方法的可能途径。
了解 YAP 和 Hippo 信号在肿瘤发生中的新兴作用，以及针对该通路成分、下游靶标或相互关联的通路开发癌症治疗方法的可能途径。
YAP 是肝癌发生中的关键致癌驱动因子，Hippo 通路的失调会导致肿瘤形成和恶性转化。靶向 YAP 和同源下游信号靶标可能在癌症治疗中有临床应用价值。
